The drug and gene delivery devices market size has grown strongly in recent years. It will grow from $0.67 billion in 2025 to $0.73 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to limited availability of advanced delivery devices, reliance on conventional administration routes, early-stage gene therapy development, growing biologics pipeline, increasing investment in research collaborations.
The drug and gene delivery devices market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to technological advancements in viral and non-viral vectors, expansion of personalized medicine and gene therapy applications, increasing regulatory approvals for innovative delivery systems, rising adoption of nanomedicine and LNPs, integration of digital monitoring and smart delivery platforms. Major trends in the forecast period include growth of targeted drug and gene therapies, rising adoption of nanoparticle-based delivery systems, increasing use of viral vectors for gene therapy, expansion of injectable and non-invasive delivery methods, focus on personalized medicine and controlled release technologies.
The increasing adoption of gene therapy is anticipated to support the expansion of the drug and gene delivery devices market going forward. Gene therapy involves modifying genetic material within a patient’s cells to treat or prevent disease and is gaining attention due to its potential to address genetic and chronic conditions at their underlying causes. The growing adoption of gene therapy has increased demand for advanced delivery systems capable of precise targeting and controlled release of therapeutic genes. Drug and gene delivery devices play a critical role in enhancing treatment effectiveness and safety. For example, in January 2025, according to the American Society of Gene & Cell Therapy, a US-based non-profit organization, the number of pre-registration gene therapy programs in Q4 2024 increased by 83% compared to Q3 2024. As a result, the expanding adoption of gene therapy is reinforcing growth across the drug and gene delivery devices market.
Leading companies operating in the drug and gene delivery devices market are focusing on developing advanced solutions, such as artificial intelligence (AI)-enabled technologies, to enhance market competitiveness. AI technology in drug delivery involves the application of advanced algorithms and data-driven models to improve delivery precision, efficiency, and therapeutic effectiveness. For example, in December 2023, Envoya Inc., a US-based developer of polymer-based nanoparticles, launched an innovative gene therapy delivery platform that combines biopolymer nanoparticles with AI. This platform is designed to address limitations of existing gene delivery methods, including safety concerns, restricted payload capacity, and limited tissue targeting associated with viral vectors and lipid nanoparticles.
In January 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Poseida Therapeutics Inc. for $1.5 billion. Through this acquisition, Roche aims to strengthen its oncology pipeline and expand its capabilities in allogeneic CAR-T cell therapies targeting blood cancers, solid tumors, and autoimmune diseases. Poseida Therapeutics Inc. is a US-based company specializing in complex immune cell therapies, including genetically modified CAR-T therapies for cancer and autoimmune disorders.
Major companies operating in the drug and gene delivery devices market are Medtronic plc, Moderna Inc., Halozyme Therapeutics Inc., Uniqure NV, Intellia Therapeutics Inc., Voyager Therapeutics Inc., sfm medical devices GmbH, Inovio Pharmaceuticals Inc., GenSight Biologics S.A., CRISPR Therapeutics, Pfizer Inc., Novartis AG, Becton Dickinson and Company, Shanghai Sunway Biotech Co Ltd, Epeius Biotechnologies Corporation, SiBiono GeneTech Co Ltd, F Hoffmann‑La Roche Ltd, Baxter International, B Braun Melsungen, Terumo Corporation, ICU Medical, Stevanato Group, Gerresheimer AG, Ypsomed, SHL Medical.
North America was the largest region in the drug and gene delivery devices market in 2025. The regions covered in the drug and gene delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug and gene delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the drug and gene delivery devices market by increasing the cost of imported materials, components, and specialized manufacturing equipment for viral and non-viral vector production. Segments such as lipid nanoparticles, polymeric nanoparticles, and viral vectors are most impacted, particularly in regions like North America and Asia-Pacific. While tariffs have raised production costs and slowed supply chains, they have also encouraged local manufacturing, investment in domestic capabilities, and innovation in alternative materials and delivery technologies.
The drug and gene delivery devices market research report is one of a series of new reports that provides drug and gene delivery devices market statistics, including drug and gene delivery devices industry global market size, regional shares, competitors with a drug and gene delivery devices market share, detailed drug and gene delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug and gene delivery devices industry. This drug and gene delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug and gene delivery devices are technologies designed to transport medications or genetic material into the body for targeted therapy. They enable precise delivery to specific tissues or cells, reducing side effects and improving treatment effectiveness.
The key vector categories of drug and gene delivery devices include viral and non-viral vectors. Viral gene delivery uses genetically modified viruses to transport therapeutic genes into target cells. The delivery methods include in situ and ex vivo techniques, and the routes of administration include oral, inhalation, transdermal, injectable, ocular, nasal, and topical routes.
The drug and gene delivery devices market consists of sales of microspheres and microneedles, electroporation devices, bio adhesive systems, and gene therapy vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug and gene delivery devices market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to technological advancements in viral and non-viral vectors, expansion of personalized medicine and gene therapy applications, increasing regulatory approvals for innovative delivery systems, rising adoption of nanomedicine and LNPs, integration of digital monitoring and smart delivery platforms. Major trends in the forecast period include growth of targeted drug and gene therapies, rising adoption of nanoparticle-based delivery systems, increasing use of viral vectors for gene therapy, expansion of injectable and non-invasive delivery methods, focus on personalized medicine and controlled release technologies.
The increasing adoption of gene therapy is anticipated to support the expansion of the drug and gene delivery devices market going forward. Gene therapy involves modifying genetic material within a patient’s cells to treat or prevent disease and is gaining attention due to its potential to address genetic and chronic conditions at their underlying causes. The growing adoption of gene therapy has increased demand for advanced delivery systems capable of precise targeting and controlled release of therapeutic genes. Drug and gene delivery devices play a critical role in enhancing treatment effectiveness and safety. For example, in January 2025, according to the American Society of Gene & Cell Therapy, a US-based non-profit organization, the number of pre-registration gene therapy programs in Q4 2024 increased by 83% compared to Q3 2024. As a result, the expanding adoption of gene therapy is reinforcing growth across the drug and gene delivery devices market.
Leading companies operating in the drug and gene delivery devices market are focusing on developing advanced solutions, such as artificial intelligence (AI)-enabled technologies, to enhance market competitiveness. AI technology in drug delivery involves the application of advanced algorithms and data-driven models to improve delivery precision, efficiency, and therapeutic effectiveness. For example, in December 2023, Envoya Inc., a US-based developer of polymer-based nanoparticles, launched an innovative gene therapy delivery platform that combines biopolymer nanoparticles with AI. This platform is designed to address limitations of existing gene delivery methods, including safety concerns, restricted payload capacity, and limited tissue targeting associated with viral vectors and lipid nanoparticles.
In January 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Poseida Therapeutics Inc. for $1.5 billion. Through this acquisition, Roche aims to strengthen its oncology pipeline and expand its capabilities in allogeneic CAR-T cell therapies targeting blood cancers, solid tumors, and autoimmune diseases. Poseida Therapeutics Inc. is a US-based company specializing in complex immune cell therapies, including genetically modified CAR-T therapies for cancer and autoimmune disorders.
Major companies operating in the drug and gene delivery devices market are Medtronic plc, Moderna Inc., Halozyme Therapeutics Inc., Uniqure NV, Intellia Therapeutics Inc., Voyager Therapeutics Inc., sfm medical devices GmbH, Inovio Pharmaceuticals Inc., GenSight Biologics S.A., CRISPR Therapeutics, Pfizer Inc., Novartis AG, Becton Dickinson and Company, Shanghai Sunway Biotech Co Ltd, Epeius Biotechnologies Corporation, SiBiono GeneTech Co Ltd, F Hoffmann‑La Roche Ltd, Baxter International, B Braun Melsungen, Terumo Corporation, ICU Medical, Stevanato Group, Gerresheimer AG, Ypsomed, SHL Medical.
North America was the largest region in the drug and gene delivery devices market in 2025. The regions covered in the drug and gene delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug and gene delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the drug and gene delivery devices market by increasing the cost of imported materials, components, and specialized manufacturing equipment for viral and non-viral vector production. Segments such as lipid nanoparticles, polymeric nanoparticles, and viral vectors are most impacted, particularly in regions like North America and Asia-Pacific. While tariffs have raised production costs and slowed supply chains, they have also encouraged local manufacturing, investment in domestic capabilities, and innovation in alternative materials and delivery technologies.
The drug and gene delivery devices market research report is one of a series of new reports that provides drug and gene delivery devices market statistics, including drug and gene delivery devices industry global market size, regional shares, competitors with a drug and gene delivery devices market share, detailed drug and gene delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug and gene delivery devices industry. This drug and gene delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug and gene delivery devices are technologies designed to transport medications or genetic material into the body for targeted therapy. They enable precise delivery to specific tissues or cells, reducing side effects and improving treatment effectiveness.
The key vector categories of drug and gene delivery devices include viral and non-viral vectors. Viral gene delivery uses genetically modified viruses to transport therapeutic genes into target cells. The delivery methods include in situ and ex vivo techniques, and the routes of administration include oral, inhalation, transdermal, injectable, ocular, nasal, and topical routes.
The drug and gene delivery devices market consists of sales of microspheres and microneedles, electroporation devices, bio adhesive systems, and gene therapy vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug and Gene Delivery Devices Market Characteristics
3. Drug and Gene Delivery Devices Market Supply Chain Analysis
4. Global Drug and Gene Delivery Devices Market Trends and Strategies
5. Drug and Gene Delivery Devices Market Analysis of End Use Industries
7. Global Drug and Gene Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug and Gene Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Drug and Gene Delivery Devices Market Segmentation
10. Drug and Gene Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Drug and Gene Delivery Devices Market
12. China Drug and Gene Delivery Devices Market
13. India Drug and Gene Delivery Devices Market
14. Japan Drug and Gene Delivery Devices Market
15. Australia Drug and Gene Delivery Devices Market
16. Indonesia Drug and Gene Delivery Devices Market
17. South Korea Drug and Gene Delivery Devices Market
18. Taiwan Drug and Gene Delivery Devices Market
19. South East Asia Drug and Gene Delivery Devices Market
20. Western Europe Drug and Gene Delivery Devices Market
21. UK Drug and Gene Delivery Devices Market
22. Germany Drug and Gene Delivery Devices Market
23. France Drug and Gene Delivery Devices Market
24. Italy Drug and Gene Delivery Devices Market
25. Spain Drug and Gene Delivery Devices Market
26. Eastern Europe Drug and Gene Delivery Devices Market
27. Russia Drug and Gene Delivery Devices Market
28. North America Drug and Gene Delivery Devices Market
29. USA Drug and Gene Delivery Devices Market
30. Canada Drug and Gene Delivery Devices Market
31. South America Drug and Gene Delivery Devices Market
32. Brazil Drug and Gene Delivery Devices Market
33. Middle East Drug and Gene Delivery Devices Market
34. Africa Drug and Gene Delivery Devices Market
36. Drug and Gene Delivery Devices Market Competitive Landscape and Company Profiles
37. Drug and Gene Delivery Devices Market Other Major and Innovative Companies
40. Drug and Gene Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Drug And Gene Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug and gene delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug and gene delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug and gene delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Vector: Viral; Non-viral2) By Method: In Situ; Ex Vivo
3) By Route Of Administration: Oral; Inhalation; Transdermal; Injectable; Ocular; Nasal; Topical
Subsegments:
1) By Viral: Adenovirus Vectors; Lentivirus Vectors; Adeno-Associated Virus (AAV) Vectors; Herpes Simplex Virus (HSV) Vectors; Retrovirus Vectors; Baculovirus Vectors; Vaccinia Virus Vectors; Sendai Virus Vectors2) By Non-Viral: Lipid Nanoparticles (LNP); Polymeric Nanoparticles; Liposomes; Dendrimers; Naked DNA/RNA Delivery; Electroporation-Based Delivery Systems; Nanoparticle-Based Delivery Systems; Polymer Micelles And Hydrogels.
Companies Mentioned: Medtronic plc; Moderna Inc.; Halozyme Therapeutics Inc.; Uniqure NV; Intellia Therapeutics Inc.; Voyager Therapeutics Inc.; sfm medical devices GmbH; Inovio Pharmaceuticals Inc.; GenSight Biologics S.A.; CRISPR Therapeutics; Pfizer Inc.; Novartis AG; Becton Dickinson and Company; Shanghai Sunway Biotech Co Ltd; Epeius Biotechnologies Corporation; SiBiono GeneTech Co Ltd; F Hoffmann‑La Roche Ltd; Baxter International; B Braun Melsungen; Terumo Corporation; ICU Medical; Stevanato Group; Gerresheimer AG; Ypsomed; SHL Medical
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug and Gene Delivery Devices market report include:- Medtronic plc
- Moderna Inc.
- Halozyme Therapeutics Inc.
- Uniqure NV
- Intellia Therapeutics Inc.
- Voyager Therapeutics Inc.
- sfm medical devices GmbH
- Inovio Pharmaceuticals Inc.
- GenSight Biologics S.A.
- CRISPR Therapeutics
- Pfizer Inc.
- Novartis AG
- Becton Dickinson and Company
- Shanghai Sunway Biotech Co Ltd
- Epeius Biotechnologies Corporation
- SiBiono GeneTech Co Ltd
- F Hoffmann‑La Roche Ltd
- Baxter International
- B Braun Melsungen
- Terumo Corporation
- ICU Medical
- Stevanato Group
- Gerresheimer AG
- Ypsomed
- SHL Medical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.73 Billion |
| Forecasted Market Value ( USD | $ 1.01 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
